Please provide your email address to receive an email when new articles are posted on . In the LOCKCYST I clinical trial, a low dose of Somatuline Depot injection for the treatment of polycystic liver ...

Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly controlled with octreotide therapy achieved normal insulin-like growth factor I levels ...

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus ...

Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...

Ipsen announced that the Food and Drug Administration (FDA) has accepted and granted Priority Review to its supplemental New Drug Application (sNDA) for Somatuline Depot (lanreotide acetate) 120mg ...

Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...

PARIS, FRANCE, 16 March 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it will invest in a new state-of-the-art electronic autoinjector for Somatuline ® Autogel ® / Somatuline ® Depot ...

Cipla has received the Food and Drug Administration’s blessing for lanreotide injection 120 mg/0.5 ml, 90 mg/0.3 ml, 60 mg/0.2 ml, which is the generic of somatuline depot (lanreotide) injection.

The FDA has approved revised labeling to include an extended dosing interval of Somatuline Depot (lanreotide; Ipsen) Injection for the treatment of acromegaly. The updated dosing recommendations allow ...

The Food and Drug Administration has given Cipla its stamp of approval for lanreotide injection. The medication is the generic of Ipsen’s Somatuline Depot. It is indicated for the treatment of ...

New Delhi: Drug major Cipla on Wednesday said it has received approval from the US health regulator to market a generic medication used to treat acromegaly and other conditions. The company has ...